|
|
| Maladies Respiratoires > Etude de marché sectorielle |
| Drug Delivery Markets, Vol III: Pulmonary Delivery Systems |
|
|
|
|
€ 1 996,00 |
Editeur
: |
Kalorama Information |
Langue
: |
Anglais |
Date de publication : |
Mars 2007 |
Taille du document : |
132 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 86 pages | Août 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,pharmacovigilance
|
| Research
focus: |
industry structure,market size and estimates, |
| Geographic
focus: |
usa,united kingdom,india,germany,thailand,nigeria,... |
| |
|
|
|
|
| 96 pages | Juillet 2006 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,...,banks
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,china,france,canada,bermuda,israel,japan,india,... |
| |
|
|
|
|
| 64 pages | Mars 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,atherosclerosis,hypertension
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france,canada |
| |
|
|
|
|
| 64 pages | Novembre 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,dyslipidemia,pharmaceutical,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france,canada,poland |
| |
|
|
|
|
| 70 pages | Septembre 2006 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,...
|
| Research
focus: |
market size and estimates,industry structure, |
| Geographic
focus: |
india,usa,china,france,united kingdom,malaysia,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Respiratory Handbook 2005-15: Novartis Moving Into the Major League
51 pages | Juin 2005 |
IntroductionThe respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets.
Future growth will be |
3 040,00 €
|
| |
| |
US Nasal Products 2004
13 pages | Juillet 2004 |
Snapdata's US Nasal Products 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the US nasal product market, and co |
240,00 €
|
| |
| |
OTC Cough and Cold Remedies in the United States
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in the United States' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line o |
198,00 €
|
| |
| |
Pulmonary Drug Delivery Technologies
362 pages | Octobre 2005 |
This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in Millions of US$.
The specific product segments analyzed are Metered Dose Inhalers (MDIs), Dry Powder Inhalers |
3 012,00 €
|
| |
| |
Stakeholder Perspectives: Pulmonary Arterial Hypertension - A small market gets big attention
59 pages | Février 2006 |
IntroductionDatamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US an |
6 460,00 €
|
| |
| |
The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector
110 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provid |
2 443,75 €
|
| |
| |
OTC Cough and Cold Remedies in the United Kingdom
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in the UK' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of |
198,00 €
|
| |
| |
US Cough Drops & Throat Lozenges 2005
12 pages | Juin 2005 |
Snapdata's US Cough Drops & Throat Lozenges 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US cough drop an |
240,00 €
|
| |
| |
Commercial Insight: Herpes and Respiratory Antivirals - Leaders Rise and Fall
218 pages | Octobre 2005 |
IntroductionWithin the herpes and respiratory antiviral subcategory HSV/VZV products have been key growth drivers, accounting for 77% of a market worth $2,190m in 2004.
Despite lost of US branded V |
9 690,00 €
|
| |
| |
Asian Airlines
181 pages | Avril 2006 |
The Asia-Pacific region has enjoyed steady expansion of air traffic since the end of the 1990s, with the exception of the first half of 2003, which was marred by the crisis that followed the outbreak |
1 795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Drug Delivery Markets, Vol III: Pulmonary Delivery Systems |
|
|
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality.
The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers and new product offerings that require advanced drug delivery. Pulmonary drug delivery offers the potential for noninvasive administration of a wide variety of macromolecules. Nearly every biotherapeutic product that treats chronic or long-term illness would benefit from noninvasive delivery by providing a competitive advantage with current therapeutics. This advantage could expand the market for each product or enable new indications to be considered.
Kalorama’s Drug Delivery Markets. Edition 2 Volume III: Pulmonary Delivery Systems, the third volume of Kalorama’s popular series focusing on global drug delivery systems markets, provides the definitive break down of the market for pulmonary delivery system markets. The report covers both pharmaceuticals sold through pulmonary delivery systems and the technologies themselves
The report provides current market size and revenue for the following main categories:
Inhalation drug delivery
Intranasal drug delivery
Kalorama believes the future of drug administration by inhalation will expand vastly and be a significant driver in this market. Serious market-watchers who are looking at new products or ways to expand existing products will find this information essential.
As part of its comprehensive cooverage, Kalorama's report includes:
A Breakdown of Demographics and Trends that will drive pulmonary delivery.
New Developments including Prodrug Technology, Electrohydrodynamic
Aerosol Delivery, Oxygen Delivery and Crystallization Technology
Detailed Discussion of Current Products in pulmonary drug delivery.
Current Market Size and Forecasts to 2010.
Review of Pipleline products
Profiles of Key Companies in the Pulmonary Delivery markets.
As part of Kalorama's trusted information-gathering process, industry executives are consulted. While government and company data is culled, it is interviews with executives that provide the foundation for market sizes and forecasts.
Kalorama's coverage of the pulmonary drug delivery market includes coverage of the following companies in this field:
3M
Alkermes
Aradigm
Elan
Nastech
Nektar
SkyePharma
|
|
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality.
The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers and new product offerings that require advanced drug delivery. Pulmonary drug delivery offers the potential for noninvasive administration of a wide variety of macromolecules. Nearly every biotherapeutic product that treats chronic or long-term illness would benefit from noninvasive delivery by providing a competitive advantage with current therapeutics. This advantage could expand the market for each product or enable new indications to be considered.
Kalorama’s Drug Delivery Markets. Edition 2 Volume III: Pulmonary Delivery Systems, the third volume of Kalorama’s popular series focusing on global drug delivery systems markets, provides the definitive break down of the market for pulmonary delivery system markets. The report covers both pharmaceuticals sold through pulmonary delivery systems and the technologies themselves
The report provides current market size and revenue for the following main categories:
Inhalation drug delivery
Intranasal drug delivery
Kalorama believes the future of drug administration by inhalation will expand vastly and be a significant driver in this market. Serious market-watchers who are looking at new products or ways to expand existing products will find this information essential.
As part of its comprehensive cooverage, Kalorama's report includes:
A Breakdown of Demographics and Trends that will drive pulmonary delivery.
New Developments including Prodrug Technology, Electrohydrodynamic
Aerosol Delivery, Oxygen Delivery and Crystallization Technology
Detailed Discussion of Current Products in pulmonary drug delivery.
Current Market Size and Forecasts to 2010.
Review of Pipleline products
Profiles of Key Companies in the Pulmonary Delivery markets.
As part of Kalorama's trusted information-gathering process, industry executives are consulted. While government and company data is culled, it is interviews with executives that provide the foundation for market sizes and forecasts.
Kalorama's coverage of the pulmonary drug delivery market includes coverage of the following companies in this field:
3M
Alkermes
Aradigm
Elan
Nastech
Nektar
SkyePharma
|
|
|
PPLSEN
|
|
|
|
|
